Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a 30-year-old male with alopecia universalis was diagnosed with ulcerative colitis, and despite treatment, he experienced no hair regrowth, highlighting that skin issues like alopecia can accompany inflammatory bowel diseases such as ulcerative colitis.

This report documents a case where a healthy female developed alopecia universalis after receiving the 9-valent HPV vaccine, highlighting the potential for autoimmune reactions and the importance of prompt medical attention.

In this case report, a 47-year-old male with Alopecia Universalis experienced complete hair regrowth after more than two years of homeopathic treatment under Dr. Batra’s care.

This case study reports a young male with alopecia universalis experienced significant hair whitening following baricitinib treatment, highlighting the need for further research on JAK inhibitors' impact on hair pigmentation and their underlying mechanisms.

In this case report, researchers observed hair regrowth in a patient with alopecia universalis and psoriasis after treatment with deucravacitinib, a TYK2 inhibitor, though they note spontaneous regrowth cannot be ruled out and suggest further controlled studies to evaluate its effects on alopecia areata.

This study described a case where both alopecia universalis and Crohn's ileitis in a 23-year-old man showed remarkable improvement with the JAK1 inhibitor upadacitinib, highlighting its potential as a treatment for patients with concurrent conditions.

This article reviews the current FDA-approved treatments for severe pediatric alopecia areata, including the use of Janus kinase inhibitors, but reports no new clinical findings.

In this case study, the researchers investigated a 44-year-old woman who developed rapidly progressing alopecia universalis after receiving a COVID-19 vaccine, and reviewed existing literature to explore potential links between COVID-19 vaccines and autoimmune hair loss conditions like alopecia areata and universalis.

This case report highlights the growing prevalence and treatability of neurosyphilis, stressing the need to consider it in neurological symptoms such as encephalopathy, facial nerve palsy, and gelastic seizures associated with the frontal lobe.

This article discusses the clinical and histological features of alopecia areata, a T-cell-mediated autoimmune disorder causing unpredictable nonscarring hair loss, without providing new clinical findings.

In this case report, the authors describe a rare association of alopecia universalis with frequently relapsing nephrotic syndrome in a 3-year-old girl, suggesting a possible genetic and immune-related cause, and note that tofacitinib treatment was ineffective in her case.

This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.

This case report presented the successful treatment of a patient with alopecia universalis using tofacitinib.

This case report describes a successful treatment of alopecia universalis in a 37-year-old female using oral tofacitinib, along with other therapies, resulting in significant hair regrowth without notable safety concerns.

Topical treatments helped a child with Down syndrome and severe hair loss regrow most of his hair.

This case report observed alopecia universalis, a complete hair loss condition, in a patient during a clinical trial with the angiotensin receptor-neprilysin inhibitor sacubitril/alisartan, indicating that ARNI therapy might be associated with such cutaneous reactions.

Scalp tattooing may trigger hair regrowth in alopecia universalis.

This case report describes a 22-month-old with alopecia universalis who showed improved hair growth after receiving combination therapy with minoxidil, corticosteroids, and excimer laser.

This case report describes an 8-year-old girl with atrichia congenita characterized by complete hair loss and papular lesions, attributed to an insertion mutation in the hairless gene.

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

In this case report, a nine-year-old girl with both chronic inflammatory demyelinating polyneuropathy and alopecia universalis showed improvement in muscle weakness and hair loss after treatment with intravenous immunoglobulin and corticosteroids.

This report describes a case of alopecia universalis successfully treated with tofacitinib, though it was associated with increased peripheral blood cytokine levels.

This case report describes the first known recovery from alopecia universalis using standard immunosuppression after lung transplantation in a patient with advanced bronchiectasis.

This report documents a rare case of alopecia universalis in an HIV-positive patient in Portugal, highlighting the changing comorbidity spectrum in this population due to increased life expectancy from antiretroviral therapy.

This case report describes a 40-year-old man with four autoimmune diseases leading to MAS, and suggests an additional classification category for MAS including autoimmune hypothyroidism, alopecia universalis, celiac disease, and immune thrombocytopenic purpura.

This case report describes a patient with alopecia universalis who had an excellent and persistent response to oral tofacitinib treatment after one year.

This case report describes successful and sustained treatment of alopecia universalis with rituximab in a patient also diagnosed with dermatomyositis, suggesting a potential role for B cells in its pathogenesis.

This study describes a case of successful treatment for alopecia universalis by combining PRP therapy with eye drops, resulting in significant hair regrowth and demonstrating no systemic side effects.

Alopecia totalis/universalis is a severe form of hair loss where all body hair is lost.

This study reports a case where treatment with the TNF alpha inhibitor infliximab successfully resolved refractory alopecia universalis in a 41-year-old woman.